Biostar Pharmaceuticals Inc
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common … Read more
Biostar Pharmaceuticals Inc (BSPM) - Net Assets
Latest net assets as of September 2017: $36.15 Million USD
Based on the latest financial reports, Biostar Pharmaceuticals Inc (BSPM) has net assets worth $36.15 Million USD as of September 2017.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($41.43 Million) and total liabilities ($5.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $36.15 Million |
| % of Total Assets | 87.26% |
| Annual Growth Rate | 9.5% |
| 5-Year Change | -36.17% |
| 10-Year Change | N/A |
| Growth Volatility | 35.23 |
Biostar Pharmaceuticals Inc - Net Assets Trend (2007–2016)
This chart illustrates how Biostar Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biostar Pharmaceuticals Inc (2007–2016)
The table below shows the annual net assets of Biostar Pharmaceuticals Inc from 2007 to 2016.
| Year | Net Assets | Change |
|---|---|---|
| 2016-12-31 | $36.88 Million | -16.69% |
| 2015-12-31 | $44.27 Million | -38.81% |
| 2014-12-31 | $72.34 Million | +15.23% |
| 2013-12-31 | $62.77 Million | +8.65% |
| 2012-12-31 | $57.77 Million | -24.38% |
| 2011-12-31 | $76.40 Million | +26.28% |
| 2010-12-31 | $60.50 Million | +47.85% |
| 2009-12-31 | $40.92 Million | +75.82% |
| 2008-12-31 | $23.27 Million | +42.86% |
| 2007-12-31 | $16.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biostar Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 139.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2016)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.64K | 0.01% |
| Other Comprehensive Income | $8.04 Million | 21.79% |
| Other Components | $31.38 Million | 85.10% |
| Total Equity | $36.88 Million | 100.00% |
Biostar Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Biostar Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AJA Health and Wellness Inc.
V:AJA
|
$221.49 |
|
AGILE PROP HOLD (A8P.SG)
STU:A8P
|
$221.53 |
|
iExalt Inc
OTCGREY:IEXA
|
$222.05 |
|
HORN PETROLEUM
MU:H73
|
$222.08 |
|
HTG Molecular Diagnostics Inc.
PINK:HTGMQ
|
$221.00 |
|
PT Trimitra Trans Persada Tbk
JK:BLOG
|
$220.77 |
|
Sabien Technology Group Plc
LSE:SNT
|
$220.05 |
|
ACME Printing and Packaging PLC
CM:ACMEN0000
|
$219.84 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biostar Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2015 to 2016, total equity changed from 44,265,139 to 36,879,177, a change of -7,385,962 (-16.7%).
- Net loss of 5,698,000 reduced equity.
- Other comprehensive income decreased equity by 2,753,697.
- Other factors increased equity by 1,065,735.
Equity Change Factors (2015 to 2016)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.70 Million | -15.45% |
| Other Comprehensive Income | $-2.75 Million | -7.47% |
| Other Changes | $1.07 Million | +2.89% |
| Total Change | $- | -16.69% |
Book Value vs Market Value Analysis
This analysis compares Biostar Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $16.40 | $0.00 | x |
| 2008-12-31 | $21.02 | $0.00 | x |
| 2009-12-31 | $35.31 | $0.00 | x |
| 2010-12-31 | $46.25 | $0.00 | x |
| 2011-12-31 | $57.53 | $0.00 | x |
| 2012-12-31 | $42.26 | $0.00 | x |
| 2013-12-31 | $38.18 | $0.00 | x |
| 2014-12-31 | $34.93 | $0.00 | x |
| 2015-12-31 | $20.02 | $0.00 | x |
| 2016-12-31 | $16.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biostar Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -239.01%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.15x
- Recent ROE (-15.45%) is below the historical average (2.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 24.33% | 24.95% | 0.78x | 1.24x | $2.33 Million |
| 2008 | 28.75% | 19.73% | 1.17x | 1.25x | $4.36 Million |
| 2009 | 25.66% | 19.69% | 1.13x | 1.15x | $6.41 Million |
| 2010 | 28.73% | 21.67% | 1.18x | 1.13x | $11.33 Million |
| 2011 | 15.93% | 13.24% | 1.11x | 1.09x | $4.53 Million |
| 2012 | -34.61% | -40.55% | 0.70x | 1.22x | $-25.77 Million |
| 2013 | 1.29% | 1.53% | 0.78x | 1.08x | $-5.47 Million |
| 2014 | 6.70% | 7.89% | 0.76x | 1.12x | $-2.39 Million |
| 2015 | -56.73% | -92.57% | 0.53x | 1.16x | $-29.54 Million |
| 2016 | -15.45% | -239.01% | 0.06x | 1.15x | $-9.39 Million |
Industry Comparison
This section compares Biostar Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biostar Pharmaceuticals Inc (BSPM) | $36.15 Million | 24.33% | 0.15x | $221.02 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |